Is 4D Molecular Therapeutics, Inc. (FDMT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.1% / 30% | 87.7% / 30% | 0.0% / 30% | 73108.11% / 5% | ✗ NOT HALAL |
| DJIM | 5.1% / 33% | 87.7% / 33% | 0.0% / 33% | 73108.11% / 5% | ✗ NOT HALAL |
| MSCI | 4.4% / 33% | 75.8% / 33% | 0.0% / 33% | 73108.11% / 5% | ✗ NOT HALAL |
| S&P | 5.1% / 33% | 87.7% / 33% | 0.0% / 33% | 73108.11% / 5% | ✗ NOT HALAL |
| FTSE | 4.4% / 33% | 75.8% / 33% | 0.0% / 50% | 73108.11% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -125.9% | |
| Operating Margin | 17.4% | |
| Net Margin | -164.4% | |
| Return on Equity (ROE) | -27.6% | |
| Return on Assets (ROA) | -17.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$135M |
| Free Cash Flow | -$138M |
| Total Debt | $25M |
| Debt-to-Equity | 4.2 |
| Current Ratio | 9.4 |
| Total Assets | $560M |
Price & Trading
| Last Close | $10.18 |
| 50-Day MA | $8.89 |
| 200-Day MA | $7.99 |
| Avg Volume | 746K |
| Beta | 3.0 |
|
52-Week Range
$2.23
| |
About 4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is 4D Molecular Therapeutics, Inc. (FDMT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), 4D Molecular Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is 4D Molecular Therapeutics, Inc.'s debt ratio?
4D Molecular Therapeutics, Inc.'s debt ratio is 5.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 4.4%.
What are 4D Molecular Therapeutics, Inc.'s key financial metrics?
4D Molecular Therapeutics, Inc. has a market capitalization of $476M, and revenue of $37,000. The company maintains a gross margin of -125.9% and a net margin of -164.4%. Return on equity stands at -27.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.